Table 4.
Multivariate Logistic Regression Analysis for ISR incidence per patients.
| Variable | ISR incidence per patients | |
|---|---|---|
| Odd Ratio (95%CI) | P value | |
| Incidence of ISR | ||
| Fosaprepitant injection (Yes vs. No) | 10.476 (2.282- 48.091) | 0.0025 |
| Age (< 50 vs. ≥ 50) | 2.177 (0.424- 11.183) | 0.3514 |
| Chemotherapy regimen (AC vs (R-)CHOP) | 4.833 (0.725- 32.202) | 0.1034 |
| Chemotherapy regimen (AC vs FEC) | 6.183 (1.019- 37.507) | 0.0476 |
| Incidence of treatment-required ISR | ||
| Fosaprepitant injection (Yes vs. No) | 31.979 (3.220-317.621) | 0.0031 |
| Age (< 50 vs. ≥ 50) | 0.731 (0.101- 5.293) | 0.7567 |
| Chemotherapy regimen (AC vs (R-)CHOP) | 3.805 (0.521- 27.793) | 0.1877 |
| Chemotherapy regimen (AC vs FEC) | 2.378 (0.299- 18.913) | 0.4130 |
CI, confidence intervals; ISR, injection site reaction; AC, doxorubicin/cyclophosphamide; (R-)CHOP, rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone; and FEC, 5-fluorouracil/epirubicin/cyclophosphamide.